Structure–activity relationship study of bone morphogenetic protein (BMP) signaling inhibitors
Top Cited Papers
- 27 June 2008
- journal article
- research article
- Published by Elsevier in Bioorganic & Medicinal Chemistry Letters
- Vol. 18 (15) , 4388-4392
- https://doi.org/10.1016/j.bmcl.2008.06.052
Abstract
No abstract availableKeywords
This publication has 34 references indexed in Scilit:
- Dysregulated BMP Signaling and Enhanced Osteogenic Differentiation of Connective Tissue Progenitor Cells From Patients With Fibrodysplasia Ossificans Progressiva (FOP)Journal of Bone and Mineral Research, 2008
- Dorsomorphin inhibits BMP signals required for embryogenesis and iron metabolismNature Chemical Biology, 2007
- Dosage-dependent requirement of BMP type II receptor for maintenance of vascular integrityBlood, 2007
- Modulation of bone morphogenetic protein signaling in vivo regulates systemic iron balanceJournal of Clinical Investigation, 2007
- Potential drug targets within bone morphogenetic protein signaling pathwaysCurrent Opinion in Pharmacology, 2007
- Bone Morphogenetic ProteinsGrowth Factors, 2004
- Synthesis and activity of new aryl- and heteroaryl-substituted 5,6-dihydro-4H-pyrrolo[1,2-b]pyrazole inhibitors of the transforming growth factor-β type I receptor kinase domainPublished by Elsevier ,2004
- Identification of Novel Inhibitors of the Transforming Growth Factor β1 (TGF-β1) Type 1 Receptor (ALK5)Journal of Medicinal Chemistry, 2002
- Role of AMP-activated protein kinase in mechanism of metformin actionJournal of Clinical Investigation, 2001
- Synthesis and reactions of 3,3′-dibromodihydrodipyrrinsJournal of the Chemical Society, Perkin Transactions 1, 1997